MedTrace Logo

Linear Growth of Children With Congenital Adrenal Hyperplasia

NCT04087148 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-09-12

No results posted yet for this study

Summary

The congenital adrenal hyperplasias (CAHs) comprise a family of autosomal recessive disorders that disrupt adrenal steroidogenesis. Three specific enzyme deficiencies are associated with virilization of affected women. The most common form is 21-hydroxylase deficiency (21-OHD) due to mutations in the 21-hydroxylase (CYP21A2) gene. Other virilizing forms include 3b-hydroxysteroid dehydrogenase type 2 (HSD3B2) and 11b-hydroxylase deficiencies associated with mutations in the HSD3B2 and 11b-hydroxylase (CYP11B1) genes, respectively.

Conditions

  • Congenital Adrenal Hyperplasia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2020-10-24
Completion
2021-10-24

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04087148 on ClinicalTrials.gov